BR112019017367A2 - detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias - Google Patents
detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias Download PDFInfo
- Publication number
- BR112019017367A2 BR112019017367A2 BR112019017367-6A BR112019017367A BR112019017367A2 BR 112019017367 A2 BR112019017367 A2 BR 112019017367A2 BR 112019017367 A BR112019017367 A BR 112019017367A BR 112019017367 A2 BR112019017367 A2 BR 112019017367A2
- Authority
- BR
- Brazil
- Prior art keywords
- sema4d
- subject
- glucose uptake
- antagonist antibody
- fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461945P | 2017-02-22 | 2017-02-22 | |
| US62/461,945 | 2017-02-22 | ||
| PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019017367A2 true BR112019017367A2 (pt) | 2020-04-14 |
Family
ID=63253999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019017367-6A BR112019017367A2 (pt) | 2017-02-22 | 2018-02-20 | detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2427212B1 (en) | 2009-05-08 | 2017-08-23 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US9243068B2 (en) | 2013-06-25 | 2016-01-26 | Vaccinex, Inc. | Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP7246320B2 (ja) | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン4d抗体 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| MX2024003883A (es) * | 2021-09-27 | 2024-08-28 | Vaccinex Inc | Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos. |
| EP4692124A1 (en) * | 2023-04-03 | 2026-02-11 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| CN102089430B (zh) * | 2008-05-09 | 2015-02-04 | Abbvie公司 | 针对渐进性糖化终极产物受体(rage)的抗体及其用途 |
| EA029023B1 (ru) * | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2018
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active Active
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
- 2018-02-20 IL IL267940A patent/IL267940B2/en unknown
- 2018-02-20 JP JP2019566047A patent/JP7626416B2/ja active Active
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 AU AU2018225493A patent/AU2018225493B2/en active Active
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
- 2018-02-20 BR BR112019017367-6A patent/BR112019017367A2/pt unknown
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en not_active Abandoned
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en not_active Ceased
-
2019
- 2019-07-05 ZA ZA2019/04431A patent/ZA201904431B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110325213A (zh) | 2019-10-11 |
| IL267940B2 (en) | 2025-04-01 |
| RU2019122337A3 (cg-RX-API-DMAC7.html) | 2021-06-09 |
| SG11201906670PA (en) | 2019-08-27 |
| WO2018156509A1 (en) | 2018-08-30 |
| AU2018225493B2 (en) | 2025-03-06 |
| ZA201904431B (en) | 2024-11-27 |
| IL267940A (en) | 2019-09-26 |
| MX2019009986A (es) | 2019-10-14 |
| IL267940B1 (en) | 2024-12-01 |
| JP2020510845A (ja) | 2020-04-09 |
| KR20190120784A (ko) | 2019-10-24 |
| AU2018225493A1 (en) | 2019-08-01 |
| RU2019122337A (ru) | 2021-03-23 |
| JP7626416B2 (ja) | 2025-02-04 |
| KR102533921B1 (ko) | 2023-05-17 |
| CA3050328A1 (en) | 2018-08-30 |
| RU2766341C2 (ru) | 2022-03-15 |
| EP3585435A4 (en) | 2020-12-16 |
| NZ755446A (en) | 2025-06-27 |
| EP3585435A1 (en) | 2020-01-01 |
| US20190383836A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| JP6875363B2 (ja) | 神経変性障害の処置のためのセマフォリン−4d結合分子の使用 | |
| KR102036938B1 (ko) | 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도 | |
| AU2021465518A1 (en) | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders | |
| EA044133B1 (ru) | Способ лечения симптомов ранней стадии болезни альцгеймера у субъекта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011071-4 PROTOCOLO 870230048153 EM 05/06/2023 18:32. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |